Filing Flows › Lifecore Biomedical (LFCR) › Q2 FY25
Lifecore Biomedical (LFCR) Q2 FY25 earnings results (second quarter fiscal 2025)
10-Q filed Jan 2, 2025
Lifecore Biomedical (LFCR) reported revenue of $32.6M for the second quarter fiscal 2025 (Q2 FY25), +8% from a year earlier and +32% from the quarter before. Operating margin was -6.0%, net loss $6.6M (20.2% of revenue).
Lifecore Biomedical, Q2 FY25: revenue $32.6M (+8% year over year), operating margin -6.0%, net loss $6.6M, operating cash flow −$6.1M. The chart follows the revenue to costs, profit and cash.
| Q2 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $32.6M | +32% | +8% |
| Operating profit | −$2.0M | — | — |
| Net earnings | −$6.6M | — | — |
| Operating cash flow | −$6.1M | — | — |
What changed
Revenue was $32.6M in Q2 FY25, up 8% year over year and up 32% from the previous quarter. CDMO was the largest line at 79% of revenue. CDMO added $1.9M year over year (up 8%), 80% of the total change.
Gross margin was 34.0%, up 1.0 points from a year earlier. Operating costs exceeded revenue by $2.0M, an operating margin of -6.0%. Operating expenses grew 14% against revenue growth of 8%. The fastest-growing cost line was SG&A (+19%). The quarter ended with a net loss of $6.6M, narrower than the previous quarter's $16.2M loss. Net interest and other expense of $4.6M was the main reason.
Operating cash flow was −$6.1M. Non-cash charges added back $2.0M of depreciation and amortization and $3.4M of share-based compensation. Working capital and other items used $5.0M. Capital expenditures of $2.4M exceeded it, leaving free cash flow of −$8.6M.
Questions
What was Lifecore Biomedical's revenue in the second quarter fiscal 2025?
Lifecore Biomedical (LFCR) reported revenue of $32.6M for the second quarter fiscal 2025 (Q2 FY25), +8% from a year earlier and +32% from the quarter before.
Was Lifecore Biomedical profitable in the second quarter fiscal 2025?
Operating loss was $2.0M (-6.0% of revenue) and net loss $6.6M.